UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported) November 14, 2003

NeoPharm, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

33-90516		51-0327886
(Commission File Number)		(IRS Employer Identification No.)

150 Field Drive, Suite 195, Lake Forest, IL 60045
(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code (847) 295-8678

(Former name or former address, if changed since last report)

Item 7. Financial Statements, Pro Forma Financials and Exhibits

Exhibit Number		Description

99.1		Press Release dated November 14, 2003 announcing NeoPharm, Inc.’s financial results for the third quarter ended September 30, 2003.

Item 12. Results of Operations and Financial Position

On November 14, 2003, NeoPharm, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2003. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this report is being furnished under Item 12 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section.

SIGNATURE PAGE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NEOPHARM INC.
Date: November 14, 2003	By:	/s/ LAWRENCE A. KENYON
		Lawrence A. Kenyon, Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)